whitepaper

Application note: A Simoa™ Bridging Assay for Anti Drug Antibody Detection

Posted: 26 November 2019 | | No comments yet

Therapeutic drugs based on biological materials (antibodies, hormones, cytokines, enzymes, fusion proteins) may have the ability to elicit an immune response in the host.

Immunogenicity of a therapeutic is defined as the unwanted elicitation of an immune response by the host to the therapeutic. The measurement of this immune response is typically assessed by quantifying the host’s production of antibodies against the therapeutic molecule. Immunogenicity of a therapeutic can be a major roadblock in the development of a product.

Here, we describe a proof of concept assay to demonstrate use of the Simoa platform as a tool to measure levels of anti drug antibodies ( against Adalimumab (Humira®). To compare performance, equivalent assays were run with the Simoa platform and a standard plate based ELISA.











To read this Application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Quanterix

Related organisations

Send this to a friend